| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lung Diseases | D008171 | 37 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Mycobacterium Infections | D009164 | 7 associated lipids |
| Sarcoidosis | D012507 | 13 associated lipids |
| Hepatolenticular Degeneration | D006527 | 3 associated lipids |
| Hyperglycemia | D006943 | 21 associated lipids |
| Carcinoma, Squamous Cell | D002294 | 14 associated lipids |
| Skin Neoplasms | D012878 | 12 associated lipids |
| Burns | D002056 | 34 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schmidt LE et al. | Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. | 2003 | Transplantation | pmid:12883193 |
| Reutzel-Selke A et al. | Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. | 2003 | Transplantation | pmid:12811235 |
| Molano RD et al. | Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. | 2003 | Transplantation | pmid:12811239 |
| Trancassini M et al. | Microbiologic investigation on patients with cystic fibrosis subjected to bilateral lung transplantation. | 2001 | Transplantation | pmid:11707748 |
| Waldman WJ et al. | Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. | 2001 | Transplantation | pmid:11707749 |
| Reese JC et al. | The effect of FK506 on canine bile flow. | 1993 | Transplantation | pmid:7504342 |
| Woodle ES et al. | FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. | 1993 | Transplantation | pmid:7504346 |
| McDiarmid SV et al. | FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. | 1995 | Transplantation | pmid:7533345 |
| Eberhard OK et al. | How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. | 1996 | Transplantation | pmid:8629294 |
| Jain A et al. | A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. | 2001 | Transplantation | pmid:11579306 |
| van Hooff JP | Pneumocystis carinii pneumonia after renal transplantation. | 1997 | Transplantation | pmid:9158038 |
| Naesens M et al. | Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. | 2006 | Transplantation | pmid:17060857 |
| Conrotto D et al. | Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. | 2006 | Transplantation | pmid:17060865 |
| Reding R et al. | Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. | 1994 | Transplantation | pmid:7507272 |
| Roberts JP et al. | Reversal of chronic rejection after treatment failure with FK506 and RS61443. | 1993 | Transplantation | pmid:7692634 |
| Kitayama T et al. | Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. | 2003 | Transplantation | pmid:12605126 |
| Storb R et al. | FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. | 1993 | Transplantation | pmid:7692635 |
| Cacciarelli TV et al. | Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. | 1996 | Transplantation | pmid:8610416 |
| Osowski CL et al. | Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. | 1996 | Transplantation | pmid:8610430 |
| Cassuto E et al. | Adherence to and Acceptance of Once-Daily Tacrolimus After Kidney and Liver Transplant: Results From OSIRIS, a French Observational Study. | 2016 | Transplantation | pmid:27653227 |
| Stojanovic J et al. | Immune Desensitization Allows Pediatric Blood Group Incompatible Kidney Transplantation. | 2017 | Transplantation | pmid:27463537 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. | 2002 | Transplantation | pmid:12490779 |
| Shapiro AM et al. | Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. | 2002 | Transplantation | pmid:12490784 |
| Ekberg H et al. | The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. | 2009 | Transplantation | pmid:19424036 |
| Jugie M et al. | Study of the impact of liver transplantation on the outcome of intestinal grafts in children. | 2006 | Transplantation | pmid:16612274 |
| Augustine JJ et al. | Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. | 2006 | Transplantation | pmid:16612276 |
| Sommerer C et al. | Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. | 2010 | Transplantation | pmid:20463649 |
| Froud T et al. | Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. | 2008 | Transplantation | pmid:19104407 |
| Tan HP et al. | Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. | 2008 | Transplantation | pmid:19104412 |
| Devlin J and Williams R | Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. | 1996 | Transplantation | pmid:8932266 |
| Song L et al. | Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. | 2014 | Transplantation | pmid:24992357 |
| MacDonald AS | Management strategies for nephrotoxicity. | 2000 | Transplantation | pmid:10910262 |
| Reyes J et al. | Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. | 2000 | Transplantation | pmid:10910279 |
| Xu H et al. | Simultaneous bone marrow and composite tissue transplantation in rats treated with nonmyeloablative conditioning promotes tolerance. | 2013 | Transplantation | pmid:23250336 |
| Fealy MJ et al. | Association of down-regulation of cytokine activity with rat hind limb allograft survival. | 1995 | Transplantation | pmid:7539555 |
| Higgins RM et al. | Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. | 2000 | Transplantation | pmid:10836393 |
| Garton T | Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. | 2002 | Transplantation | pmid:12352898 |
| Ekser B et al. | Hepatic function after genetically engineered pig liver transplantation in baboons. | 2010 | Transplantation | pmid:20606605 |
| Paterson DL et al. | Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. | 1998 | Transplantation | pmid:9753337 |
| Woodle ES et al. | Liver transplantation in the first three months of life. | 1998 | Transplantation | pmid:9753340 |
| van Hooff JP et al. | Tacrolimus and posttransplant diabetes mellitus in renal transplantation. | 2005 | Transplantation | pmid:15940032 |
| Mourer JS et al. | Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients. | 2013 | Transplantation | pmid:23715049 |
| Gaber AO et al. | Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. | 2013 | Transplantation | pmid:23715050 |
| Cohen JB et al. | Belatacept Compared With Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study. | 2017 | Transplantation | pmid:27941427 |
| Günther M et al. | Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. | 2001 | Transplantation | pmid:11233913 |
| Rezeig MA et al. | Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. | 1997 | Transplantation | pmid:9175820 |
| Hricik DE et al. | Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. | 2003 | Transplantation | pmid:14508357 |
| Uemoto S et al. | Experience with FK506 in living-related liver transplantation. | 1993 | Transplantation | pmid:7679528 |
| Talento A et al. | A single administration of LFA-1 antibody confers prolonged allograft survival. | 1993 | Transplantation | pmid:7679531 |
| Mor E et al. | Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7513098 |